<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>Insight数据库 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-10T20:28:38+08:00</updated>
  <subtitle>丁香园 Insight 数据库（db.dxy.cn），拥有申报、临床、上市、药企等 10 大核心数据。致力于分享医药行业政策解读、药企大事和药品申报情报等</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>半年一次！诺华长效降脂药在华启动 III 期临床，首个 PCSK9 靶向 siRNA 药物</title>
    <updated>2020-11-10T17:25:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/C8ojDcY_Kyh6W-9rznvsdw</id>
    <link href="https://mp.weixin.qq.com/s/C8ojDcY_Kyh6W-9rznvsdw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>总额 1.39 亿美元！恒瑞 PD-L1/TGF-β 双抗授权给韩国东亚公司</title>
    <updated>2020-11-10T17:25:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/b_SXYgLCwZLo0awmgZWAuw</id>
    <link href="https://mp.weixin.qq.com/s/b_SXYgLCwZLo0awmgZWAuw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内进展最快，齐鲁制药罗米司亭启动 III 期临床</title>
    <updated>2020-11-10T17:25:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/N_PJkCK_4BVWIK2rJEw3lg</id>
    <link href="https://mp.weixin.qq.com/s/N_PJkCK_4BVWIK2rJEw3lg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>罗氏 CD3×CD20 双抗 Glofitamab 首次在华启动临床</title>
    <updated>2020-11-10T17:25:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/4KTs0bXEO91nBEKPPNQWjQ</id>
    <link href="https://mp.weixin.qq.com/s/4KTs0bXEO91nBEKPPNQWjQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>辉瑞/BioNTech 新冠疫苗有效率达 90%！国内合作伙伴复星医药涨停</title>
    <updated>2020-11-10T17:25:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/ciG4A2h9iZBer9QFwxFf4g</id>
    <link href="https://mp.weixin.qq.com/s/ciG4A2h9iZBer9QFwxFf4g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>今日 5 款仿制药通过一致性评价，3 个为前三家，来自信立泰、华海…</title>
    <updated>2020-11-09T17:48:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/9LyvFfxoqW_LXC4v2vvOaA</id>
    <link href="https://mp.weixin.qq.com/s/9LyvFfxoqW_LXC4v2vvOaA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>刚刚！贝达药业「恩莎替尼」审评状态变化，预计即将获批</title>
    <updated>2020-11-09T17:48:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/5wJPGxcc9evU2wtzFw5q5g</id>
    <link href="https://mp.weixin.qq.com/s/5wJPGxcc9evU2wtzFw5q5g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>荣昌生物-B 上市首日大涨 34%，首个国产 ADC 药物即将获批</title>
    <updated>2020-11-09T17:48:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/j_XGBLn93XeH3648ubpHyw</id>
    <link href="https://mp.weixin.qq.com/s/j_XGBLn93XeH3648ubpHyw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞 2 款新药获批临床</title>
    <updated>2020-11-09T17:48:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/D7JGyxM2-KkTbojiXPME_w</id>
    <link href="https://mp.weixin.qq.com/s/D7JGyxM2-KkTbojiXPME_w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>卫材「仑伐替尼」甲状腺癌适应症获批，2020 年即将参与医保谈判</title>
    <updated>2020-11-09T17:48:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/9G55dqhpsBfo_yZXAEaIbA</id>
    <link href="https://mp.weixin.qq.com/s/9G55dqhpsBfo_yZXAEaIbA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>汇聚津门，三十位行业大咖论道细胞产业发展新趋势</title>
    <updated>2020-11-09T17:48:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/Rlue4l4yVz37GZ0jm0rbBQ</id>
    <link href="https://mp.weixin.qq.com/s/Rlue4l4yVz37GZ0jm0rbBQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2 个 1 类新药已报产，荣昌生物明日港交所挂牌上市</title>
    <updated>2020-11-08T12:01:12+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-08:/s/WAj5VHY9vNNzBy_7uehzWA</id>
    <link href="https://mp.weixin.qq.com/s/WAj5VHY9vNNzBy_7uehzWA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>本周 6 款注射剂过评，3 款为首家</title>
    <updated>2020-11-06T18:03:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/aYc1Ja52K5VhDm_ZhKv_wQ</id>
    <link href="https://mp.weixin.qq.com/s/aYc1Ja52K5VhDm_ZhKv_wQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百元支架时代开启！我们真要实现「支架自由」了吗？</title>
    <updated>2020-11-06T18:03:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/aciJgfQ3m8WfgegNdr6-1w</id>
    <link href="https://mp.weixin.qq.com/s/aciJgfQ3m8WfgegNdr6-1w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医药新股破发频频，投资逻辑生变？</title>
    <updated>2020-11-06T14:46:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/iFgOCOhGJ0gFxf_UlDHhtA</id>
    <link href="https://mp.weixin.qq.com/s/iFgOCOhGJ0gFxf_UlDHhtA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>一线治疗鼻咽癌！恒瑞 PD-1 第 6 个适应症拟纳入优先审评</title>
    <updated>2020-11-06T14:46:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/KjcoUQLnQ3ngCE44M7XonQ</id>
    <link href="https://mp.weixin.qq.com/s/KjcoUQLnQ3ngCE44M7XonQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州三季报，PD-1 卖了 3.3 亿元</title>
    <updated>2020-11-06T14:46:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/yKmRXIb1EtxKCBaK0e10jQ</id>
    <link href="https://mp.weixin.qq.com/s/yKmRXIb1EtxKCBaK0e10jQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>冠脉支架集采拟中选结果公布！均价1.3万降到 700 元</title>
    <updated>2020-11-05T14:26:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/PrRJx4NItdzVHdEGzUP7xQ</id>
    <link href="https://mp.weixin.qq.com/s/PrRJx4NItdzVHdEGzUP7xQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球销售额15亿美元，青峰药业「拉考沙胺注射液」首仿获批</title>
    <updated>2020-11-04T16:12:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-04:/s/aWfVUyWuAzjMyCE0obS4Rw</id>
    <link href="https://mp.weixin.qq.com/s/aWfVUyWuAzjMyCE0obS4Rw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>10 亿重磅品种，扬子江药业「注射用泮托拉唑钠」第二家过评</title>
    <updated>2020-11-04T16:12:26+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-04:/s/fELo8iGvUI31-4X07FHUoA</id>
    <link href="https://mp.weixin.qq.com/s/fELo8iGvUI31-4X07FHUoA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>